Jeffrey Sparks, MD
Rheumatology · Boston, MANPI 1356546063
Payments from drug & device makers
Across 579 payments — averaging $1640.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$414K
- E.r. Squibb & Sons, L.L.C.$334K
- AbbVie$37K
- Pfizer$35K
- Boehringer Ingelheim$23K
- Novartis$20K
- plus $87K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 39 | $414,384 |
| E.r. Squibb & Sons, L.L.C. | 72 | $333,706 |
| AbbVie | 86 | $36,895 |
| Pfizer | 55 | $35,270 |
| Boehringer Ingelheim | 20 | $22,736 |
| Novartis | 73 | $20,269 |
| Janssen Scientific Affairs, LLC | 123 | $16,657 |
| Johnson & Johnson | 7 | $9,767 |
| Merck | 8 | $9,617 |
| Gilead | 14 | $9,098 |
| UCB, Inc. | 12 | $7,641 |
| Fresenius Kabi USA, LLC | 2 | $5,100 |
| Sun Pharmaceutical Industries Inc. | 8 | $5,023 |
| Janssen Global Services, LLC | 2 | $4,320 |
| Inova Diagnostics, Inc. | 1 | $3,750 |
| Amgen | 2 | $2,500 |
| Sobi, Inc | 1 | $2,160 |
| Invivyd Inc | 1 | $2,013 |
| ANI Pharmaceuticals, Inc. | 1 | $1,950 |
| Lilly USA, LLC | 9 | $1,903 |
| Sanofi | 14 | $1,902 |
| AstraZeneca | 4 | $1,637 |
| Genentech, Inc. | 17 | $738 |
| Genentech USA, Inc. | 7 | $723 |
| Assertio Therapeutics, Inc. | 1 | $154 |
How this compares
$949,910 in reported general payments places this provider in the 90th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Boston
- John StoneBoston$7.1M
- Sebastian UnizonyBoston$4M
- Tuhina NeogiBoston$3.7M
- George TsokosBoston$3.1M
- Tanya LaidlawBoston$1.7M
- Deepak RaoBoston$1.7M
- Katherine LiaoBoston$1.7M
- Peter NigrovicBoston$1.5M
- Marilyn PikeBoston$1.4M
- Michael BrennerBoston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.